摘要
目的:分析SDF-1在乳腺癌患者外周血中的表达水平,探讨其临床意义。方法:Elisa法检测乳腺癌患者术前及术后血清SDF-1水平,分析其与乳腺癌临床病理特征的关系。结果:乳腺癌患者术前(69例)血清SDF-1水平明显高于正常对照组(20例)(6406.7±1302.5 pg/m L vs 5217.4±1225.7 pg/m L),有明显统计学差异(P<0.01),发生远处转移的乳腺癌患者(11例)血清SDF-1水平明显高于未发生转移者(58例)(7656.4±784.1 pg/m L vs 6169.7±1364.6 pg/m L),差异具有明显统计学意义(P<0.01)。ER及Her-2表达阳性乳腺癌的患者SDF-1水平较ER及Her-2表达阴性者低,差异亦有统计学意义(P<0.05)。结论:SDF-1可能是预测乳腺癌发生及远处转移的重要标志物。
Objective： This study was conducted to investigate the value of the pretreatment circulating stromal cell derived factor-1（SDF-1） in patients with breast carcinoma. Methods： We measured SDF-1 serum concentrations and evaluated the relationship between serum SDF-1 and clinical factors in preoperative and postoperative breast cancer patients. Results： Serum levels of SDF-1 is higher in breast cancer patients than in controls（P〈0.01）, Serum levels of SDF-1 is higher in metastatic patients than non-metastatic patients（P〈0.01）. Serum levels of SDF-1 is higher in ER and Her-2 positive breast cancer patients than ER and Her-2 negative patients（P〈0.05）. Conclusion： SDF-1 might serve as a possible marker predicting development or distant metastasis in breast cancer.
出处
《现代生物医学进展》
CAS
2015年第6期1080-1083,1100,共5页
Progress in Modern Biomedicine
基金
崇明县科委科研基金(CKY2010-10)
